SCHEMBL30133135

SCHEMBL30133135

CCOC(=O)C1CCc2c1sc(NC(=O)CN)c2C(=O)c1c(F)cccc1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.38
KDM4E B2RXH2 3/20 0.38
TSHR P16473 3/20 0.38
POLB P06746 1/20 0.38
RAB9A P51151 2/20 0.38
MAPT P10636 5/20 0.37
TP53 P04637 3/20 0.37
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
NPC1 O15118 1/20 0.36
ALDH1A1 P00352 3/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
HTT P42858 2/20 0.35
GAA P10253 2/20 0.35
HSD17B10 Q99714 1/20 0.35
HPGD P15428 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
PDE4B Q07343 1/20 0.35
GABRP O00591 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30133161 0.94 MAPT (0.40) KDM4ETSHRPOLBMAPTTP53
SCHEMBL30133129 0.92 SMN1; SMN2 (0.39) SMN1; SMN2KDM4ETSHRPOLBRAB9A
SCHEMBL27238444 0.88 GABRP (0.38) SMN1; SMN2KDM4ERAB9AMAPTTP53
SCHEMBL30133176 0.85 KDM4E (0.42) SMN1; SMN2KDM4ETSHRPOLBRAB9A
SCHEMBL30133169 0.83 RAB9A (0.41) SMN1; SMN2KDM4ETSHRPOLBRAB9A
SCHEMBL30133170 0.82 PDE4B (0.38) SMN1; SMN2KDM4EPOLBMAPTTP53
SCHEMBL27238459 0.81 PDE4B (0.39) SMN1; SMN2KDM4ERAB9AMAPTTP53
SCHEMBL27238479 0.79 LMNA (0.40) SMN1; SMN2KDM4EPOLBRAB9AMAPT
SCHEMBL30133143 0.79 PDE4B (0.37) SMN1; SMN2TSHRPOLBMAPTTP53
SCHEMBL29281266 0.78 ALDH1A1 (0.41) SMN1; SMN2KDM4ETSHRPOLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240190889-A1 NEW CYCLOPENTA-THIENO-DIAZEPINE DERIVATIVES AS GABA A GAMMA1 POSITIVE ALLOSTERIC MODULATORS HOFFMANN-LA ROCHE INC. (US) 2024-06-13 US disclosed
EP-4380940-A1 NEW CYCLOPENTA-THIENO-DIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM F. Hoffmann-La Roche AG (CH) 2024-06-12 EP disclosed
WO-2023012130-A1 NEW CYCLOPENTA-THIENO-DIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM F. HOFFMANN-LA ROCHE AG (CH) 2023-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240190889-A1 NEW CYCLOPENTA-THIENO-DIAZEPINE DERIVATIVES AS GABA A GAMMA1 POSITIVE ALLOSTERIC MODULATORS GABRA1, GABRA5, GABRB1 SMN1; SMN2 1314/4885KDM4E 2009/4885TSHR 1800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.